Two University of Arizona College of Medicine – Phoenix Faculty Named Fellows of the National Academy of Inventors

NAI Fellows are recognized for their inventions that have major impacts on society

Contact: Al Bravo, (602) 827-2022

PHOENIX – Gholam A. Peyman, MD, who invented LASIK and many other advances, and Frederic Zenhausern, PhD, MBA, who has developed a rapid DNA processor, both of the University of Arizona College of Medicine – Phoenix, have been named Fellows of the National Academy of Inventors (NAI). Election to NAI Fellow status is a high professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.

The 143 innovators elected to NAI Fellow status represent 94 universities and governmental and non-profit research institutes. Together, they hold more than 5,600 U.S. patents.

Included in the 2013 class are 26 presidents and senior leadership of research universities and non-profit research institutes, 69 members of the National Academies, five inductees of the National Inventors Hall of Fame, six recipients of the U.S. National Medal of Technology and Innovation, and nine Nobel Laureates among other major awards and distinctions.

The NAI Fellows will be inducted by Deputy U.S. Commissioner for Patents Andy Faile, from the U.S. Patent and Trademark Office, during the 3rd Annual Conference of the National Academy of Inventors, on March 7, 2014, in Alexandria, Va. Fellows will be presented with a special trophy and a rosette pin.

Academic inventors and innovators elected to the rank of NAI Fellow were nominated by their peers for outstanding contributions to innovation in areas such as patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation.

Two Faculty Named Fellows of The National Academy of Inventors

 —

Gholam A. Peyman, MD
Gholam A. Peyman, MDGholam A. Peyman, MD, is a faculty member at UA College of Medicine – Phoenix, professor of Optical Sciences and Engineering at the UA, Professor Emeritus at Tulane University and Co-Director of Arizona Retinal Specialists.

Dr. Peyman, an ophthalmologist and vitreoretinal surgeon has been granted 148 patents. His most widely known invention is LASIK eye surgery, a vision correction procedure designed to allow people to see clearly without glasses. Dr. Peyman’s inventions cover a broad range of novel medical devices, intra-ocular drug delivery, surgical techniques, laser and optical instruments, as well as new methods of diagnosis and treatment.

He has won numerous honors and awards, including being inducted into the Hall of Fame of Ophthalmology. His awards include The Presidential National Medal of Innovation & Technology, Lifetime Achievement Award of the American Academy of Ophthalmology, the first translational research award from the Association for Research in Vision and Ophthalmology and inclusion in the American Society of Cataract and Refractive Surgery Hall of Fame.

Dr. Peyman has published 900 articles, 10 books, and serves on the editorial boards of the Journal of Retina, Ophthalmic Surgery, and Laser Imaging and Retina. He is also a Fellow of respected organizations such as the Association for Research in Vision and Ophthalmology and The Macula Society.

Frederic Zenhausern, PhD, MBA
Frederic Zenhausern, PhD, MBAFrederic Zenhausern is a professor and Director of the Center for Applied Nanobioscience and Medicine at the UA College of Medicine – Phoenix. The center uniquely applies a combination of advances in nanoscience, microelectromechanical systems, molecular biology, and genomics to a new generation of biological tools and sensors based on nano and microscale technologies. Zenhausern is also a professor at the Translational Genomics Research Institute (TGen).

Applying interdisciplinary science approaches to medicine, Zenhausern’s work is aimed at early diagnostics of human diseases, in particular, cancer, infectious and cardiovascular diseases. His team is developing platform technologies to translate molecular analysis into clinical tools and adoption of novel technologies for point-of-care diagnostics applications.

The Microfluidic DNA Analysis System (MiDAS), a desktop printer-sized box that is described as robust and user-friendly, is one of Zenhausern’s innovations. The integrated DNA analyzer can be transported directly to a point-of-care or deployed in a mobile setting, eliminating some of the issues that arise when collecting and shipping a specimen from a remote site to a centralized laboratory for molecular testing. The core technology is also enabling the rapid automation of preparation of a biological sample for interfacing with various high-resolution analytical instrumentations, such as Next Generation Sequencing, which are emerging diagnostic tools in personalized medicine.

A similar platform was configured for genomic assays ready for implementations in medical countermeasures against radiological and nuclear disasters, and also applicable in clinical settings for predicting which patients are most sensitive to radiation in guiding personalized treatment, and preventing the development of toxicities that may result from radiotherapy. These innovations are described in multiple patents, which led to significant federal funding of Arizona academic institutions, and to generating commercial interest and licensing from multiple U.S. companies, also contributing to Arizona’s economic development.

Zenhausern has co-authored more than 70 scientific publications and is named on many pending and more than a dozen issued U.S. patents in various domains ranging from DNA sequencing to optical data storage. Zenhausern’s responsibilities also include leading clinical research at the personalized medicine research laboratory at Scottsdale Healthcare Research Institute and serving on several corporate scientific boards and international consortia in life sciences.

The University of Arizona College of Medicine – Phoenix admitted its inaugural class of first-year medical students in August 2007. The College of Medicine – Phoenix currently has 282 students training to be physicians. The University of Arizona College of Medicine – Phoenix inspires and trains individuals to become exemplary physicians, scientists and leaders who are life-long learners and inquisitive scholars and who will embrace professionalism, innovation and collaboration to optimize health and healthcare for all. For more information, visit phoenixmed.arizona.edu.

The National Academy of Inventors® is a 501(c)(3) non-profit member organization comprised of U.S. and international universities, and governmental and non-profit research institutions, with over 3,000 individual inventor members and Fellows spanning more than 200 institutions, and growing rapidly. It was founded in 2010 to recognize and encourage inventors with patents issued from the U.S. Patent and Trademark Office, enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate and mentor innovative students, and translate the inventions of its members to benefit society. The NAI edits the multidisciplinary journal, Technology and Innovation – Proceedings of the National Academy of Inventors, published by Cognizant Communication Corporation (NY). www.academyofinventors.org

The Translational Genomics Research Institute (TGen) is a Phoenix-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.